CADL at a glance
Candel Therapeutics, Inc. (CADL, SEC CIK 1841387) filed its latest 10-K annual report on March 12, 2026, a 10-Q quarterly report on November 12, 2026, an 8-K current report on November 12, 2026 and Form 4 insider filings as recently as November 5, 2026. SignalX summarizes each filing with AI and tracks the company's insider trades and institutional holders.
- As of September 30, 2026, 24 institutional investment managers tracked by SignalX reported holding Candel Therapeutics, Inc. (CADL) shares worth $165.3 million in 13F-HR filings.
- The most recent insider open-market sale reported on Form 4 was by Tak Paul Peter on September 11, 2026 of 59,379 shares at $10.46 per share.
- In the last 90 days, CADL insiders reported 0 open-market purchases ($0) and 2 open-market sales ($3.2M) on Form 4, a net sale of $3.2M.
Source: SEC EDGAR (XBRL financial data, 13F-HR and Form 4 filings).
- Insiders · 90 days
- 0 buys · 2 sells
- Net −$3.2M
- 13F holders
- 24 funds
- $165.3M · +0 vs prior quarter
- Latest 8-K
- Nov 12, 2026
- Item 2.02
AI 10-Q Quarterly Report Analysis
Latest 10-Q, quarter ended Sep 30, 2026
Risk Factors
- Newly added regulatory risk: June 2026 FDA guidance may require additional clinical data despite a single-trial approval pathway
- Most material financial update: $203.1 million cash expected to fund operations into Q2 2028
- Debt risk: Trinity facility totals $130.0 million, with $50.0 million outstanding and covenant-triggered acceleration possible
- Near-term operational risk: Small eligible brain-cancer population may delay linoserpaturev trial enrollment
- Compliance risk: GDPR violations may trigger fines up to €20 million or 4% of annual global revenues
Management Discussion & Analysis
- Revenue $0, unchanged YoY, no product sales generated
- Net loss $21.9M vs $11.3M YoY, operating expenses $23.0M vs $13.2M
- R&D highest spending line: $15.6M vs $8.5M, driven by aglatimagene development
- Cash and equivalents $203.1M, operating cash use $58.3M, financing cash inflow $142.6M
- Outlook: cash runway into Q2 2028, additional capital required for NSCLC phase 3 and commercialization preparation
AI summary of the CADL 10-Q filed . Generated from the filing text; verify against the original.View on SEC EDGAR10-K vs 10-Q vs 8-K
AI 8-K Current Report Analysis
The most recent material events, by 8-K item
Item 2.02: Results of Operations and Financial Condition
- Q3 2026 financial results announced for quarter ended September 30, 2026
- Full results and management commentary available in Exhibit 99.1
Item EX-99.1: Item EX-99.1
- Q3 revenue-free biotech reported net loss $21.9M, versus $11.3M, with R&D spending rising to $15.6M to advance aglatimagene programs
- Cash $203.1M, up from $119.7M at year-end, supports operations into Q2 2028 under current plans, reducing near-term financing pressure
Item 8.01: Other Events
- New ATM facility authorizes up to $50 million in additional common-stock sales through Jefferies
- Prior 2025 ATM fully utilized, with approximately $50 million sold as of November 12, 2026
Item 5.02: Departure/Appointment of Directors or Principal Officers
- Board expanded from 10 to 11 directors; Martine Zimmermann appointed independent Class III director through 2027 annual meeting
- Regulatory expertise spanning FDA, EMA and Japanese authorities strengthens oversight of drug-development and approval strategy
Item EX-99.1: Item EX-99.1
- Martine Zimmermann appointed to Candel’s Board effective September 8, 2026
- More than 30 years of regulatory and quality experience strengthens oversight ahead of planned BLA submission
Item 7.01: Regulation FD Disclosure
- Martine Zimmermann, PharmD appointed to Candel Therapeutics’ Board of Directors
- Board addition may strengthen pharmaceutical development and commercialization expertise
AI summaries of CADL 8-K current reports filed with the SEC. What 8-K item codes mean
SignalX for CADL
Don't miss the next CADL filing
- Alerts as it files. A push when CADL files an 8-K or an insider trades.
- Fund moves. Which tracked funds opened, added or cut CADL, by share count.
- Ask anything. An AI agent that reads every CADL filing and answers with sources.
Recent Insider Transactions (Form 4)
Latest reported trades by officers, directors and 10% owners
| Insider | Type | Date | Shares | Price |
|---|---|---|---|---|
| Ostrovsky Maria | A | Nov 3, 2026 | 315,000 | - |
| Loggia Nicoletta | A | Sep 30, 2026 | 380 | $8.68 |
| Manning Paul B | A | Sep 30, 2026 | 2,189 | $8.68 |
| PAPA JOSEPH C | A | Sep 30, 2026 | 1,325 | $8.68 |
| Tak Paul Peter | Sell | Sep 11, 2026 | 59,379 | $10.46 |
| Tak Paul Peter | M | Sep 10, 2026 | 125,000 | $1.55 |
| Tak Paul Peter | Sell | Sep 10, 2026 | 220,866 | $11.50 |
| Tak Paul Peter | M | Sep 10, 2026 | 125,000 | - |
Financial SummaryXBRL
| Metric | FY2023 | FY2024 | FY2025 |
|---|---|---|---|
| Profitability | |||
| Operating Income | -$38.4M | -$33.4M | -$48.3M |
| Net Income | -$37.9M | -$55.2M | -$38.2M |
| Balance Sheet | |||
| Total Assets | $41.2M | $106.9M | $125.2M |
| Equity | $12.7M | $66.3M | $51.9M |
| ROE | -297.7% | -83.2% | -73.5% |
| Per Share | |||
| EPS | $-1.31 | $-1.74 | $-0.72 |
| Cash Flow | |||
| Operating CF | - | -$27.0M | -$38.3M |
| CapEx | $457K | $16K | $587K |
Source: XBRL data in Candel Therapeutics, Inc. (CADL)'s 10-K filings on SEC EDGAR, in USD. Compare across companies →
13F Fund Holdings: Quarterly Trend
Latest: Q3 2026Aggregate CADL share value held by 13F filers tracked by SignalX, by quarter.
Quarterly totals table
| Quarter | Funds | Total value |
|---|---|---|
| Q3 2026 | 24 | $165.3M |
| Q2 2026 | 24 | $265.3M |
| Q1 2026 | 23 | $97.3M |
| Q4 2025 | 18 | $87.4M |
| Q3 2025 | 19 | $74.8M |
| Q2 2025 | 19 | $74.0M |
| Q1 2025 | 18 | $61.1M |
| Q4 2024 | 10 | $59.0M |
- State Street Corp+257.3K (+7%)
- Vanguard Capital Management LLC+253.0K (+9%)
- Citadel Advisors LLC+227.7K (+156%)
- BlackRock+213.9K (+4%)
- Vanguard Portfolio Management LLC+103.0K (+24%)
- Millennium Management−122.5K (-11%)
- Citigroup−43.3K (-51%)
- Wells Fargo & Co−37.4K (-65%)
- Two Sigma Investments−7.3K (-22%)
- Invesco Ltd−878 (-2%)
- FMR LLC (Fidelity)−10.99M
Source: 13F-HR filings on SEC EDGAR (aggregated from 155 fund-quarter rows). Reflects only 13F filers tracked by SignalX, not the full institutional ownership universe. How 13F filings work
CADL filing archive
AI analysis pages for each 10-K, 10-Q and 8-K
Latest 2026 SEC Filings: 10-K, 10-Q, 8-K & Form 4
| Form | Filing date | Period | Analysis | SEC |
|---|---|---|---|---|
| 8-K | Nov 12, 2026 | - | Analysis | - |
| 8-K | Nov 12, 2026 | - | Analysis | - |
| 10-Q | Nov 12, 2026 | Sep 30, 2026 | Analysis | |
| 4 | Nov 5, 2026 | - | - | - |
| 4 | Oct 2, 2026 | - | - | - |
| 4 | Oct 2, 2026 | - | - | - |
| 4 | Oct 2, 2026 | - | - | - |
| 4 | Sep 11, 2026 | - | - | - |
| 8-K | Sep 10, 2026 | - | Analysis | - |
| 4 | Sep 10, 2026 | - | - | - |
| 8-K | Sep 9, 2026 | - | Analysis | - |
| 4 | Aug 19, 2026 | - | - | - |
| 8-K | Aug 13, 2026 | - | Analysis | - |
| 10-Q | Aug 13, 2026 | Jun 30, 2026 | Analysis | |
| SC 13G | Jul 27, 2026 | - | - | |
| 4 | Jul 8, 2026 | - | - | - |
| 4 | Jul 1, 2026 | - | - | - |
| 4 | Jul 1, 2026 | - | - | - |
| 4 | Jul 1, 2026 | - | - | - |
| 4 | Jul 1, 2026 | - | - | - |
| 4 | Jul 1, 2026 | - | - | - |
| 4 | Jun 24, 2026 | - | - | - |
| 4 | Jun 24, 2026 | - | - | - |
| 4 | Jun 24, 2026 | - | - | - |
| 4 | Jun 24, 2026 | - | - | - |
Related Health Care companies
- FDMT · 4D Molecular Therapeutics, Inc.Biological Products, (No Diagnostic Substances)
- ADPT · Adaptive Biotechnologies CorpBiological Products, (No Diagnostic Substances)
- ADMA · ADMA BIOLOGICS, INC.Biological Products, (No Diagnostic Substances)
- ALEC · Alector, Inc.Biological Products, (No Diagnostic Substances)
- ALLO · Allogene Therapeutics, Inc.Biological Products, (No Diagnostic Substances)
- AMGN · AmgenBiological Products, (No Diagnostic Substances)
- AVXL · ANAVEX LIFE SCIENCES CORP.Biological Products, (No Diagnostic Substances)
- APGE · Apogee Therapeutics, Inc.Biological Products, (No Diagnostic Substances)
CADL SEC filings: frequently asked questions
Are CADL insiders buying or selling?
In the last 90 days, Candel Therapeutics, Inc. (CADL) officers, directors and 10% owners reported no open-market purchases and 2 open-market sales worth $3.2 million by 1 insider on Form 4. Many insider sales are pre-planned or for taxes, so purchases usually carry more information.
Which institutions hold CADL stock?
As of September 30, 2026, the largest Candel Therapeutics, Inc. (CADL) holders among the 13F filers tracked by SignalX were BlackRock ($54.1 million), State Street Corp ($39.7 million), Vanguard Capital Management LLC ($30.8 million), Millennium Management ($10.1 million), Vanguard Portfolio Management LLC ($5.6 million). 13F-HR reports are filed up to 45 days after each quarter ends.
What did CADL report in its latest 8-K?
Candel Therapeutics, Inc. (CADL) filed an 8-K on November 12, 2026 reporting Item 2.02 (Results of Operations and Financial Condition). Q3 2026 financial results announced for quarter ended September 30, 2026.
What are the latest CADL SEC filings?
Candel Therapeutics, Inc. (CADL) filed its latest 10-K annual report on March 12, 2026, a 10-Q quarterly report on November 12, 2026, an 8-K current report on November 12, 2026 and a Form 4 insider filing on November 5, 2026.
What is CADL's SEC CIK number?
Candel Therapeutics, Inc. (CADL)'s SEC Central Index Key (CIK) is 1841387. EDGAR lists every CADL filing under that number.
Ask anything about CADL
The research agent reads CADL's filings, financials, insider trades and 13F holders, then answers with sources.